Optimi Health Corp. (OPTH) Form 6-K — Jun 10, 2026
Optimi Health Corp. (OPTH) announced the completion of its first export of naturally derived psilocybin to the United Kingdom. The shipment includes psilocybin biomass and finished 5mg capsules, which will support a planned Phase 2 clinical trial in the UK. The export was executed under authorization from Health Canada and the UK Home Office, utilizing product manufactured at Optimi’s GMP facility in Princeton, British Columbia.
Key figures
- Trial phase
- Phase 2
- Capsule strength
- 5mg
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.